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Background/Aims: Endoscopic ultrasound (EUS) plays a 
crucial role in the assessment and treatment of low-grade 
gastric mucosa-associated lymphoid tissue (MALT) lympho-
ma; however, interobserver variation, inadequate accuracy 
in judging the depth of tumor invasion, and histological het-
erogeneity of the tumor can limit its role. Thus, we have as-
sessed the role of 18F-FDG PET scans in the management of 
Helicobacter pylori-infected gastric MALT lymphoma. Meth-
ods: Eighteen patients with H. pylori-infected low-grade gas-
tric MALT lymphoma underwent an 18F-FDG PET scan prior 
to receiving H. pylori eradication therapy. We analyzed these 
patients’ clinicopathologic data and measured the baseline 
and change in the metabolic activity of the tumor using 
standardized uptake values (SUVs). Results: Two patients 
failed to achieve complete remission of the low-grade gastric 
MALT lymphoma after successful H. pylori eradication. The 
baseline SUVs were significantly higher in these patients 
compared to successfully treated patients, 13.35±0.07 vs 
2.98±0.93, respectively (n=2 vs n=16, p<0.001). The re-
duction in the SUV was signifi cantly greater in the complete 
remission patients compared to treatment failure patients 
(p=0.018). Conclusions: A high SUV at baseline 18F-FDG 
PET and a lower reduction in the SUV within 3 months after 
eradication therapy are associated with treatment failure in 
H. pylori-positive low-grade gastric MALT lymphoma patients 
undergoing eradication treatment. (Gut Liver 2011;5:308-314)
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INTRODUCTION
The low-grade gastric mucosa-associated lymphoid tissue 
(MALT) lymphoma is an indolent tumor, which is strongly 
associated with Helicobacter pylori infection.1 H. pylori eradi-
cation is a well-established initial treatment modality in H. 
pylori-positive low-grade gastric MALT lymphoma confined 
to the gastric mucosa or submucosa. Many reports affirm that 
eradication treatment alone shows a greater than 80% com-
plete remission (CR) rate and durable remission. Although the 
majority of the tumors regress within 1 month of eradication 
therapy, the achievement of CR may take up to one year. Some 
experts define residual MALT lymphoma lasting over one year 
after H. pylori eradication as treatment failure.2 Since there are 
patients with tumors demonstrating a mixture of low-grade 
MALT lymphoma and diffuse large B cell lymphoma (DLBCL) 
on histopathological examination, such a long period of wait-
ing for CR after H. pylori eradication therapy poses the risk of 
tumor progression. It is important, therefore, to define the clini-
copathologic factors related with initial treatment failure by H. 
pylori eradication. To date, the factors known to be related to 
initial treatment failure in low-grade gastric MALT lymphoma 
are as follows: MALT lymphoma not related with H. pylori in-
fection, deeper tissue invasion, and genetic abnormalities such 
as t(11;18).3-5
Determining the depth of tumor invasion, while important 
in predicting the response to H. pylori eradication treatment, 
poses some diagnostic challenges. Scanning the entire stomach 
is often technically difficult, and deeper invasive lesions of syn-
chronous, multicentric gastric MALT lymphomas may be missed 
during scanning with endoscopic ultrasound (EUS). Also, recent 
data show suboptimal interobserver agreement in assessing the 
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depth of tumor invasion of gastric MALT lymphomas by EUS.6 
Furthermore, the histological heterogeneity of the tumor makes 
it difficult to choose an appropriate treatment modality. Propor-
tions of large cell histology within the MALT lymphoma tissue 
determine the prognosis7 and the classification of MALT lym-
phoma.8 The failure to recognize large cell aggregates on biopsy 
often misleads physicians, causing them to initiate ineffective 
therapies against ‘hidden’ much more aggressive neoplasm.9,10
18F-FDG PET scan is widely used as a cancer staging modal-
ity. By assessing the metabolic status of the stomach collective-
ly, PET scan may provide additional information of proportion 
of large cell aggregates which has relatively higher metabolic 
activity and may not be regressed by H. pylori eradication. PET 
scans also can be useful in predicting the response to cancer 
treatment early in the course of therapy.11 Here, we assess the 
role of PET scan in planning treatment modalities of H. pylori-
associated low-grade gastric MALT lymphoma.
MATERIALS AND METHODS
From May 1992 to September 2005, 71 patients were diag-
nosed with primary gastric low-grade MALT lymphoma by his-
topathological exam at Yonsei University, Severance Hospital. 
Among them, 26 patients underwent an 18F-FDG PET scan be-
fore any anti-tumor treatments. Eight patients underwent initial 
treatment other than H. pylori eradication and were excluded 
from analysis. We analyzed the clinical data in the remaining 
18 patients with H. pylori-positive low-grade gastric MALT 
lymphoma. Patients diagnosed with mixed pathology with dif-
fuse large B cell lymphoma or who were found to have second-
ary involvement of the stomach from systemic disease were 
excluded from the analysis. 
All the patients’ 18F-FDG PET scans were performed with a 
GEⓇ advanced PET scanner, after 60 minutes from injection of 
0.068-0.14 mCi/kg of 18F-FDG. Some patients received another 
follow-up PET scan within 3 months from the end of initial 
treatment. The quantification of FDG uptake (standardized 
uptake value, SUV) was conducted by one nuclear medicine 
expert. Most of the patients (15 out of 18) underwent EUS as 
part of an initial staging exam. EUS was performed with radial 
sector scanning echoendoscopes (GFUM-240, GFUM-2000; 
Olympus, Tokyo, Japan) with variable frequencies of 5, 7.5, 
12, and 20 MHz or MiniprobeⓇ with a frequency of 20 MHz. 
Acoustic coupling with the gastric wall was obtained by using 
a water-filling technique or using a water-filled balloon on the 
instrument’s tip. A bone marrow exam was also included in 
the staging evaluation. H. pylori infection was considered to be 
present if either histology, rapid urease test, or a 18C-urea breath 
test was positive.
All of the patients underwent H. pylori eradication therapy 
Table 1. Clinical Characteristics and Treatment Results
Patient
no.
Sex Age
EUS*
Pattern of lesion
FDG uptake (SUV) Initial Tx 
result†T LN Baseline Follow-up Change
  1 F 34 M - Erythematous, localized 2.7 2.8 0.1 (3.7%) CR
  2 F 58 M + Ulcerative, multicentric 1.8 ND ND CR
  3 F 70 ND ND Erosive, localized 3.0 ND ND CR
  4 M 74 ND ND Erythematous, multicentric 3.0 ND ND CR
  5 M 48 SM - Ulcerative, localized 4.0 3.0 -1.0 (-25.0%) CR
  6 M 48 M - Polypoid, localized 1.8 1.6 -0.2 (-11.1%) CR
  7 F 46 SM - Ulcerative, localized 2.4 1.4 -1.0 (-41.7%) CR
  8 M 40 SM - Ulcerative, multicentric 2.0 1.2 -0.8 (-40.0%) CR
  9 F 52 SM + Protruding, multicentric 13.3 15.3 2.0 (15.0%) Failure
10 F 39 M - Erythematous, diffuse 2.5 3.0 0.5 (20.0%) CR
11 F 47 M - Erythematous, localized 3.5 1.2 -2.3 (-65.7%) CR
12 M 52 SM - Erosive, localized 4.8 4.3 -0.5 (-10.4%) CR
13 F 62 M - Erythematous, diffuse 3.2 2.7 -0.5 (-15.6%) CR
14 F 46 M - Ulcerative, diffuse 4.2 ND ND CR
15 M 54 SM - Ulcerative, diffuse 2.5 ND ND CR
16 F 67 ND ND Protruding, localized 4.2 ND ND CR
17 F 64 SM - Ulcerative, diffuse 2.1 2.6 0.5 (23.8%) CR
18 F 72 B - Ulcerative, diffuse 13.4 ND ND Failure
*Endoscopic ultrasound findings (M, mucosal; SM, submucosal; B, beyond SM; ND, no available data); †Result of initial treatment (CR, complete 
remission).
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as anti-tumor treatment. Therapy consisted of a seven or 14-
day course of triple therapy with rabeprazole (20 mg b.i.d.), 
amoxicillin (1,000 mg b.i.d.), and clarithromycin (500 mg b.i.d.). 
After the completion of eradication treatment, follow-up endo-
scopic examinations were performed at 3-6 month intervals or 
annually if sustained remission was achieved. Initial treatment 
failure was defined as the presence of aggressive histopathology 
other than low-grade MALT lymphoma on follow-up biopsy or 
persistence of low-grade MALT lymphoma in biopsy specimens 
at one year post-treatment. Data were expressed as a mean±SD. 
Statistically significant differences were determined by Student’s 
t-test or two-tailed Fisher’s exact test. Statistical analysis was 
performed with SPSS Statistical Package, version 12.0 (SPSS 
Inc., Chicago, IL, USA).
RESULTS
A total of 18 patients were diagnosed with primary low-grade 
gastric MALT lymphoma on multiple endoscopic biopsies. All 
the cases were H. pylori-infected. The depth of tumor invasion 
and presence of other organ involvement were assessed before 
the initiation of H. pylori eradication therapy (Table 1). One pa-
tient (patient number 4) had concomitant MALT lymphoma of 
the bronchus, and the remaining patients had no synchronous 
lesion in other organs.
After the completion of initial eradication treatment, 16 pa-
tients achieved CR with no need for additional treatments. The 
two patients were defined as treatment failures. Despite com-
pleting H. pylori eradication treatment, one patient had biopsy 
results consistent with residual low-grade MALT lymphoma at 
10-month follow-up, and radiation therapy was then initiated. 
The follow-up biopsy of another patient with treatment failure 
showed progression into the DLBCL, and the patient was as-
signed to receive intravenous chemotherapy (Fig. 1). 
The treatment failure group tended to be older than the 
CR group, but this was not statistically significant (p=0.331, 
Table 2). Depth of tumor invasion, as determined by EUS, was 
divided into two stages, tumors limited to the mucosa and 
tumors extending beyond the mucosa. We failed to find any 
significant difference in the depth of tumor invasion between 
the two groups. On the other hand, baseline FDG uptake was 
significantly higher in the treatment failure group compared 
to CR group, 13.35±0.07 SUV vs 2.98±0.93 SUV, suggesting 
significantly higher metabolic activity in the treatment failure 
group (p<0.001). A more evident reduction of FDG uptake was 
achieved in the CR group (-0.52±0.84 SUV, -16.2%±28.1%) 
compared to the treatment failure group, and one treatment 
failure patient showed 15.0% increase in FDG uptake in a post-
treatment PET scan (p=0.018, Table 2, Fig. 1). Patients who 
demonstrated tumor regression after H. pylori eradication ther-
apy had less baseline FDG uptake and a more marked decrease 
in uptake after therapy than the treatment failure group (Table 
2, Fig. 2). After the achievement of complete remission, no re-
currence was seen in any of the 18 patients during the median 
Fig. 1. The initial biopsy is consistent with low-grade mucosa-
associated lymphoid tissue (MALT) lymphoma by H&E staining (×100) 
(A) and by immunohistochemical staining for L26/CD79a-positive, 
CD3-negative cells (×200) (B), but a subsequent study confirms the 
diagnosis of diffuse large B cell lymphoma (×200) (C).
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follow-up of 25.4 months (range, 1.3 to 82.8 months).
DISCUSSION
Primary gastric lymphoma represents the most common 
presentation of extranodal lymphoma. H. pylori infection is 
strongly associated with low-grade gastric MALT lymphoma, 
and regression of the tumor has been reported in 50% to 100% 
of patients after eradication therapy. There is a higher risk of 
treatment failure, if MALT lymphoma is not related with H. py-
lori, has deeper tissue invasion, or is associated with a genetic 
abnormality such as t(11;18).3-5 There are some low-grade MALT 
lymphomas that exist in combination with diffuse large B cell 
lymphoma, which can progress during the follow-up period 
after eradication therapy. It has clinical impact, therefore, to 
define clinicopathologic parameters in low-grade gastric MALT 
lymphoma that correlate with those tumors that do not respond 
to H. pylori eradication therapy.
Application of a PET scan with the glucose analog 18F-FGD 
for cancer staging or assessment of therapy response is widely 
accepted in the majority of cases of solid cancers and lympho-
mas.12,13 By estimating the baseline or changes in SUV, PET scan 
allows clinicians to predict or monitor treatment response early 
in the course of therapy. Some studies have already reported the 
useful role of 18F-FDG PET scan in MALT lymphoma.14-16 But 
these studies consisted of primary tumors arising from hetero-
geneous organs and included only nine to ten primary gastric 
MALT lymphoma patients. This is the largest case series ever, 
including only primary gastric MALT lymphoma. More impor-
tantly, this is the first report that shows that metabolic imaging 
correlates with clinical outcomes in patients with low-grade 
gastric MALT lymphoma. Our results demonstrated that a base-
line PET scan, with or without follow-up imaging after treat-
ment, allows for the prediction of tumor response to H. pylori 
eradication therapy in patients with gastric low-grade MALT 
lymphoma. High SUV on baseline PET scan or lower degrees of 
reduction in SUV within 3 months after the eradication treat-
ment were associated with treatment failure. 
EUS plays an important role in the staging of MALT lym-
phoma, and it is the best diagnostic modality to guide the initial 
treatment course and to help determine the need to change the 
treatment plan. Despite this fact, a multicenter evaluation of in-
Table 2. Comparison of the Complete Remission Group with the Treatment Failure Group
Eradication group CR group (n=16) Treatment failure group (n=2)
Age 53.1±11.7 62.0±14.1 p=0.331
H. pylori positivity 16/16 (100%) 2/2 (100%) NA
Depth of invasion by EUS
M=7/13* M=0/2
p=0.467beyond M=6/13*
(SM=6/13, beyond SM=0/13)
beyond M=2/2
(SM=1/2, beyond SM=1/2)
Baseline SUV 2.98±0.93 13.35±0.07 p<0.001
Change of SUV
-0.52±0.84† 
   (-16.2±28.1%)†
2.0‡
(15%)‡
p=0.018
(p=0.317)
EUS, endoscopic ultrasound; SUV, standardized uptake value.
*Only 13 patients out of 16 were studied by EUS; †Only 10 patients out of 16 were studied by follow-up PET; ‡Only one patient out of 2 was 
studied by follow-up PET.
Fig. 2. Baseline standardized uptake values (SUVs) and changes in the SUV according to clinical outcome. The boxes represent the 25th and 75th 
percentile, the thick horizontal bars represent the median, and the upper and lower horizontal bars represent the maximum and minimum data.
CR, complete remission.
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terobserver agreement with respect to endosonographic staging 
of gastric MALT lymphoma revealed suboptimal results.6 The 
kappa value of submucosal or deeper lesions were below 0.40, 
even down to 0.20 after treatment, and that of mucosal lesions 
was around 0.40. Whether the depth of tumor invasion should 
be a risk factor for disease progression still remains controver-
sial. Recently, El-Zahabi et al.17 analyzed 19 H. pylori-positive 
patients with gastric MALT lymphoma and demonstrated that 
tumors with submucosal infiltration have a significantly lower 
rate of complete remission after eradication compared with mu-
cosal lesion (12.5% vs 77.8%, p=0.007). Another study showed 
that most gastric lymphomas restricted to the submucosa 
achieved complete remission, whereas deeper tissue invasion 
beyond the submucosal layer failed to show remission.18 On 
the other hand, another report demonstrated that the absence 
of nodal involvement is the only predictor of tumor regression 
with multivariate analysis.4 Given the suboptimal interobserver 
agreement and the need for a highly skilled endosonographer 
and the undetermined value of the depth of tissue invasion in 
determining the risk of tumor progression, the role of EUS in 
judging the treatment response in low-grade gastric MALT lym-
phomas remains unclear.
Histological heterogeneity is another obstacle in planning the 
treatment of gastric MALT lymphomas. The amount and pattern 
of large-cell populations within MALT lymphoma tissue differ-
entiates low-grade MALT lymphoma from the much more ag-
gressive DLBCL. MALT lymphoma containing over 5-10% large 
cells is known to indicate a worse prognosis.7,8 The distribution 
of large cells within the neoplasm is extremely heterogeneous,9 
and it is well known that MALT lymphoma involvement in the 
stomach is sometimes multifocal or diffuse.19 Therefore, it is no 
surprise that there is a significant discrepancy in the diagnosis 
between surgical and endoscopic samples, and the difference 
seems not to be overcome by multiple biopsy samples.7,10
Overcoming the limits of EUS and the histological heteroge-
neity of the tumor is critical, and we demonstrate that the 18F-
FDG PET scan can be a tool to assess the stomach as a whole. 
In this study, the baseline SUV of patients in the CR group was 
very low, 2.98±0.93 (range, 1.8 to 4.8). This relatively low meta-
bolic activity may indicate that tumors in this group have a low 
large-cell component, which correlates with a good response to 
H. pylori eradication therapy in these patients. 
We observed two patients who failed to achieve remission 
during follow-up. Their baseline SUVs were higher than 13.0, 
and this indicated that their lesions expressed significantly 
higher metabolic activity. Again, this possibly indicates that the 
tumors may contain a relatively greater large-cell component, 
which may not be detected by sampled biopsies. Failure to rec-
ognize these more aggressive histopathological features may 
lead to ineffective treatment courses and a greater risk of disease 
progression. One of the patients within this study who failed to 
respond to H. pylori eradication therapy showed progression to 
a DLBCL (Fig. 3), and achieved remission after a series of com-
bination intravenous chemotherapy. It is likely that the patient’s 
initial biopsy samples did not include the heterogeneously dis-
tributed large-cell portion, leading to the misdiagnosis of a DL-
BCL as a low-grade MALT lymphoma. This underscores the ob-
vious need to overcome the histological heterogeneity of these 
Fig. 3. Examples of baseline and 
follow-up PET images. (A) Patient 
number 7. The stomach wall shows 
diffusely increased uptake from 
baseline (baseline standardized up-
take value [SUV], 2.4) that become 
fainter after eradication therapy 
(follow-up SUV, 1.4). Complete 
remission is maintained during the 
30-month follow-up. (B) Patient 
number 9. High-grade FDG uptake is 
noted at the antrum (baseline SUV, 
13.3). Even after eradication therapy, 
a residual low-grade mucosa-asso-
ciated lymphoid tissue (MALT) lym-
phoma persists. The high baseline 
SUV correlats with follow-up images 
(follow-up SUV, 15.3). This patient 
fails to gain complete remission dur-
ing the 10-month follow-up period 
after the initiation of treatment.
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tumors through alternative diagnostic modalities. PET scanning 
assesses the metabolic status of the stomach collectively. These 
images may indicate the status of sporadically distributed large 
cells within the stomach and minimize the misdiagnosis of 
DLBCL as low-grade MALT lymphoma. Although not included 
in our study, we encountered another case of gastric DLBCL in 
a 63-year-old female patient. Her initial biopsy was consistent 
with low-grade MALT lymphoma. Baseline FDG uptake in that 
patient was relatively high, 11.1 SUV, and immediate repeat 
endoscopic reexamination confirmed that the tumor was actu-
ally DLBCL. By identifying high baseline metabolic activity and 
initiating radiation therapy or chemotherapy, the risk of delay-
ing treatment while waiting for as long as 12 months after the 
eradication therapy2 to achieve MALT remission can be avoided. 
By quantification of FDG uptake, expressed as SUV, it is 
possible to compare the degree of uptake and to measure the 
change in value in the same subject. Some studies have shown 
that chemotherapy-resistant tumors show a relatively higher 
pretreatment SUV or less degree of reduction in SUV after treat-
ment. These findings suggest the need to alter treatment modali-
ties early in the clinical course.11 Unfortunately, at present, there 
are no generally accepted criteria for a metabolic response in 
FDG-PET studies, and it should be established for every specific 
neoplasm. In a study evaluating 50 lesions,20 a change in SUV 
can be considered significant only when the difference between 
the baseline and follow-up PET scan is more than 0.9. For the 
eleven patients with low-grade MALT lymphoma who under-
went follow-up PET, only a small reduction in SUV (-0.18±1.10 
SUV; range, -2.3 to 2.0 SUV) was noted in this study. These data 
demonstrated that the utility of PET scans in the early identifi-
cation of tumors with poor response to eradication therapy may 
be suboptimal for indolent low-grade gastric MALT lymphomas. 
It may be more reasonable to use baseline 18F-FDG PET results 
as a tool to predict treatment failure with H. pylori eradication 
therapy and to determine whether this treatment course should 
be pursued in patients with gastric low-grade MALT lymphoma. 
Furthermore, PET might discriminate MALT lymphoma with 
a substantial large-cell component responding to eradication 
treatment from a non-responding tumor. Some reports and a 
prospective study showed early stage DLBCL with features of 
MALT lymphoma that would regress after H. pylori eradication 
therapy,21-23 but this remains uncertain. In that context, using 
PET imaging may be of some utility in detecting tumors with 
low metabolic activity reflecting, DLBCL mixed with a low-
grade MALT lymphoma component, which might respond to H. 
pylori eradication therapy. We have encountered two patients 
with gastric DLBCL with SUV below 5.0 (data not included; 4.1 
and 4.9 SUV, mucosal and submucosal invasion on EUS, re-
spectively) who regressed into low-grade MALT lymphoma on 
gastrectomized pathology or follow-up endoscopic biopsies.
In conclusion, we have examined the role of 18F-FDG PET 
scan in formulating treatment options for low-grade gastric 
MALT lymphomas with H. pylori infection. Patients with high 
baseline SUV or less of a decline in SUV after H. pylori eradica-
tion treatment showed a significantly higher rate of treatment 
failure. By defining high metabolic activity, a baseline PET scan 
may suggest a MALT tumor with histologic features consistent 
with DLBCL as well. Baseline PET scans may be of great utility 
in treatment planning for patients with low-grade gastric MALT 
lymphoma, especially when mixed cellularity with DLBCL is 
suspected. We suggest that physician do re-biopsy or re-staging 
if the initial lesion has intense FDG uptake on PET scan.
Our study has some limitations. This study was limited by a 
small number of subjects, and with only two treatment failure 
cases, it is impossible to compare the range of baseline SUV 
and changes in SUV. In addition, only 11 patents were followed 
with PET imaging. Consequently, no cutoff value for discrimi-
nating responders from non-responders could be obtained. 
Also cost-effectiveness of performing PET in patient with low 
grade MALT lymphoma is a matter to be concerned. The Korean 
National Insurance Corporation has covered most of the fee 
of PET scan and only about twenty US dollars are charged to 
patients. But this is not the case in many other countries. We 
suggest physician perform PET scan especially in patients hav-
ing diffuse lesion that may be hard to scan all properly with 
EUS, suspicious deep invasion, or mixed cellularity with DLBCL. 
Even with these shortcomings, this is the largest case series ever 
consisting with only gastric low grade MALT lymphoma, and 
it is remarkable that this is the first report suggesting metabolic 
image correlate with clinical outcomes of eradication therapy. It 
is warranted to conduct a well-designed, prospective study with 
a statistically sufficient sample size to determine that PET im-
age can overcome the clinical limit of EUS in managing gastric 
MALT lymphoma.
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